A Phase 3 interventional study of Romiplostim and Placebo in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed at 33 sites in 3 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-09.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 15th largest by enrollment, is the only one that started in 2012, is one of 13 in phase 3, and was the 14th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2012, is one of 10 in phase 3, and was the 15th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric patients with Immune thrombocytopenia purpura (ITP) as measured by durable platelet response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.
Drug: Romiplostim
Participants received weekly subcutaneous placebo for 24 weeks.
Drug: Placebo
The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
Also known as: AMG 531, Nplate®
Matching placebo administered by subcutaneous injection
Percentage of Participants With a Durable Platelet Response
A participant with durable platelet response was defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10\^9/L during the last 8 weeks of treatment (platelet counts obtained from week 18 to week 25). If a platelet count from a participant was not available (missing) in a certain week, that week was imputed as non-response for that participant. Platelet counts were not deemed as a positive response for 4 weeks after the administration of rescue medication.
Time frame: Week 18 to week 25
Percentage of Participants With an Overall Platelet Response
Overall platelet response is defined as either a durable platelet response or transient platelet response. Durable platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 6 or more times during week 18 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medication. Transient platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 4 or more times during week 2 to week 25 measurements but without durable platelet response. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.
Time frame: Week 2 to week 25
Number of Weeks With Platelet Response
Number of weeks with platelet counts ≥ 50 x 10\^9/L during week 2 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.
Time frame: Week 2 to week 25
Percentage of Participants Who Received Rescue Medication During the Treatment Period
Rescue medication is any medication (other than excluded medications) that is intended to increase platelet counts or prevent bleeding.
Time frame: 24 weeks
Total Number of Composite Bleeding Episodes
A composite bleeding episode was defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinical significant bleeding event during weeks 2 through 25 of the treatment period. A clinically significant bleeding event was defined as a Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade ≥ 2 bleeding event.
Time frame: Week 2 to week 25
Number of Participants With Adverse Events
A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life threatening (places the subject at immediate risk of death), * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other significant medical hazard. Adverse events were graded for severity according to the CTCAE version 3.0 grading scale, where Grade 3 = moderate, Grade 4 = life-threatening and Grade 5 = fatal. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to study drug. This relationship was determined by a "yes" or "no" response to the question: "Is there a reasonable possibility that the event may have been caused by study drug?"
Time frame: From the first dose of study drug until 4 weeks after last dose; 28 weeks.
This study was conducted at 27 centers in the United States, Canada, and Australia. Participants were enrolled from 24 January 2012 to 03 September 2014.
| Milestone | Placebo | Romiplostim |
|---|---|---|
| Started | 20 | 42 |
| Received treatment | 19 | 42 |
| Completed | 18 | 41 |
| Not completed | 2 | 1 |
| Withdrew: Ineligibility determined | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
A participant with durable platelet response was defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10\^9/L during the last 8 weeks of treatment (platelet counts obtained from week 18 to week 25). If a platelet count from a participant was not available (missing) in a certain week, that week was imputed as non-response for that participant. Platelet counts were not deemed as a positive response for 4 weeks after the administration of rescue medication.
| percentage of participants | Placebo | Romiplostim |
|---|---|---|
| Percentage of Participants With a Durable Platelet Response | 10.0 (1.2 to 31.7) | 52.4 (36.4 to 68.0) |
Overall platelet response is defined as either a durable platelet response or transient platelet response. Durable platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 6 or more times during week 18 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medication. Transient platelet response was defined as weekly platelet count ≥ 50 x 10\^9/L for 4 or more times during week 2 to week 25 measurements but without durable platelet response. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.
| percentage of participants | Placebo | Romiplostim |
|---|---|---|
| Percentage of Participants With an Overall Platelet Response | 20.0 (5.7 to 43.7) | 71.4 (55.4 to 84.3) |
Number of weeks with platelet counts ≥ 50 x 10\^9/L during week 2 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.
| weeks | Placebo | Romiplostim |
|---|---|---|
| Number of Weeks With Platelet Response | 1.0 (0 to 22) | 12.0 (0 to 24) |
Rescue medication is any medication (other than excluded medications) that is intended to increase platelet counts or prevent bleeding.
| percentage of participants | Placebo | Romiplostim |
|---|---|---|
| Percentage of Participants Who Received Rescue Medication During the Treatment Period | 45.0 (23.1 to 68.5) | 40.5 (25.6 to 56.7) |
A composite bleeding episode was defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinical significant bleeding event during weeks 2 through 25 of the treatment period. A clinically significant bleeding event was defined as a Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade ≥ 2 bleeding event.
| bleeding episodes | Placebo | Romiplostim |
|---|---|---|
| Total Number of Composite Bleeding Episodes | 4.0 ± 6.9 | 1.9 ± 4.2 |
A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal, * life threatening (places the subject at immediate risk of death), * requires in-patient hospitalization or prolongation of existing hospitalization, * results in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other significant medical hazard. Adverse events were graded for severity according to the CTCAE version 3.0 grading scale, where Grade 3 = moderate, Grade 4 = life-threatening and Grade 5 = fatal. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to study drug. This relationship was determined by a "yes" or "no" response to the question: "Is there a reasonable possibility that the event may have been caused by study drug?"
| participants | Placebo | Romiplostim |
|---|---|---|
| Any adverse event (AE) | 19 | 41 |
| Serious adverse events (SAE) | 1 | 10 |
| AE leading to discontinuation of study drug | 0 | 0 |
| AE leading to discontinuation from study | 0 | 0 |
| Grade 3 AE | 3 | 6 |
| Grade 4 AE | 1 | 2 |
| Grade 5 AE | 0 | 0 |
| Treatment-related adverse events (TRAE) | 5 | 11 |
| Treatment-related serious adverse events | 0 | 1 |
| TRAE leading to discontinuation of study drug | 0 | 0 |
| TRAE leading to discontinuation from study | 0 | 0 |
| TRAE Grade 3 | 0 | 1 |
| TRAE Grade 4 | 0 | 0 |
| TRAE Grade 5 | 0 | 0 |
Collected over From the first dose of study drug until 4 weeks after last dose; 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/19 (5.3%) | 19/19 (100%) |
| Romiplostim | — | 10/42 (23.8%) | 41/42 (97.6%) |
| Event | Placebo | Romiplostim |
|---|---|---|
| Animal BiteInjury, poisoning and procedural complications | 1/19 | 0/42 |
| HaematuriaRenal and urinary disorders | 1/19 | 0/42 |
| HeadacheNervous system disorders | 0/19 | 2/42 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/19 | 2/42 |
| ThrombocytosisBlood and lymphatic system disorders | 0/19 | 1/42 |
| NauseaGastrointestinal disorders | 0/19 | 1/42 |
| VomitingGastrointestinal disorders | 0/19 | 1/42 |
| PyrexiaGeneral disorders | 0/19 | 1/42 |
| BronchiolitisInfections and infestations | 0/19 | 1/42 |
| Urinary Tract InfectionInfections and infestations | 0/19 | 1/42 |
| Event | Placebo | Romiplostim |
|---|---|---|
| HeadacheNervous system disorders | 11/19 | 17/42 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 10/19 | 20/42 |
| ContusionInjury, poisoning and procedural complications | 7/19 | 21/42 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/19 | 16/42 |
| NauseaGastrointestinal disorders | 7/19 | 8/42 |
| LacerationInjury, poisoning and procedural complications | 6/19 | 2/42 |
| PetechiaeSkin and subcutaneous tissue disorders | 6/19 | 10/42 |
| FatigueGeneral disorders | 5/19 | 7/42 |
| Mouth HaemorrhageGastrointestinal disorders | 4/19 | 11/42 |
| VomitingGastrointestinal disorders | 4/19 | 11/42 |
| Age, Continuous(years) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Mean | 9.4 ± 4.7 | 9.7 ± 4.1 | 9.6 ± 4.3 |
| Age, Customized(participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| ≥ 1 - < 6 years | 4 | 8 | 12 |
| ≥ 6 - < 12 years | 9 | 18 | 27 |
| ≥ 12 - < 18 years | 7 | 16 | 23 |
| Sex: Female, Male(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Female | 11 | 24 | 35 |
| Male | 9 | 18 | 27 |
| Race/Ethnicity, Customized(participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Black or African American | 2 | 6 | 8 |
| Multiple | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 1 | 5 | 6 |
| White | 15 | 26 | 41 |
| Platelets(10^9/L) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Mean | 19.9 ± 19.3 | 17.5 ± 10.7 | 18.3 ± 13.9 |
The record gives a start of Jan 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 11 months after primary completion. A results delay was requested in Jan 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →